Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies-Reference-Cited by-同舟云学术

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

Published:2018-12-04 Issue:6 Volume:125 Page:892-901
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ahn Myung‐Ju¹^ORCID,Tsai Chun‐Ming²,Shepherd Frances A.³,Bazhenova Lyudmila⁴,Sequist Lecia V.⁵,Hida Toyoaki⁶,Yang James C. H.⁷,Ramalingam Suresh S.⁸^ORCID,Mitsudomi Tetsuya⁹,Jänne Pasi A.¹⁰,Mann Helen¹¹,Cantarini Mireille¹²,Goss Glenwood¹³^ORCID

Affiliation:

1. Section of Hematology‐Oncology Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Korea

2. Department of Oncology, Taipei‐Veterans General Hospital and School of Medicine National Yang‐Ming University Taipei Taiwan

3. Department of Medical Oncology and Hematology Princess Margaret Cancer Center Toronto Ontario Canada

4. Department of Medicine University of California‐San Diego, Moores Cancer Center La Jolla California

5. Department of Hematology Oncology Massachusetts General Hospital Boston Massachusetts

6. Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya Japan

7. Department of Oncology National Taiwan University Hospital, National Taiwan University Cancer Center Taipei City Taiwan

8. Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta Georgia

9. Department of Thoracic Surgery Kindai University Faculty of Medicine Osaka‐Sayama Japan

10. Lowe Center for Thoracic Oncology The Belfer Institute for Applied Cancer Science, Dana‐Farber Cancer Institute Boston Massachusetts

11. Biometrics and Information Science AstraZeneca Cambridge United Kingdom

12. Global Medicines Development, AstraZeneca Alderley ParkUnited Kingdom

13. Division of Medical Oncology The Ottawa Hospital Cancer Center, University of Ottawa Ottawa Ontario Canada

Funder

AstraZeneca

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31891

Reference21 articles.

1. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

5. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients;World Journal of Surgical Oncology;2023-11-25

2. A Durable Response to Osimertinib in an Elderly Patient With EGFR T790M Positive Metastatic Non–Small-Cell Lung Cancer After Progression on Erlotinib;American Journal of Therapeutics;2023-09

3. Prognosis of different bone metastases patterns in EGFR-mutant advanced lung adenocarcinoma patients;2023-08-10

4. How to Treat EGFR-Mutated Non–Small Cell Lung Cancer;JACC: CardioOncology;2023-08

5. Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report;Frontiers in Oncology;2023-07-03